Key Highlights
- Net loss for the third quarter of 2026 was USD 49.2 million, or USD 0.50 per share, against USD 45.5 million, or USD 0.87, a year earlier, with USD 26.9 million from a non-cash change in Warrant liabilities.
- Loss from operations narrowed to USD 19.5 million from USD 21.2 million as Research and Development fell to USD 10.6 million from USD 13.3 million, while selling, general and administrative expense rose to USD 9.2 million.
- Cash, cash equivalents and short-term investments were USD 48.4 million on September 30, 2026, with a Working Capital Deficit of USD 38.0 million, before a November offering with net proceeds of about USD 80.5 million.
- The FDA granted Accelerated Approval to VOCERYQ on October 30, 2026, and management expects to make it available to order and ship about 60 days after approval.
Warrant Revaluation Inflates the Headline Loss
Inovio Pharmaceuticals (NASDAQ:INO) filed its Quarterly Report on November 10, 2026 and held its Earnings Call the same day. Net loss was USD 49.2 million, but the operating picture was smaller: loss from operations was USD 19.5 million. The gap came largely from a USD 26.9 million non-cash charge for the change in Fair Value of common stock warrant liabilities, plus USD 3.2 million of other expense that includes a charge of about USD 1.1 million when July warrants were issued. Revenue was USD 299,000, from preclinical research services, against none a year earlier. Weighted shares were 98.6 million against 52.2 million.
A USD 80.5 Million Raise Follows a Working Capital Deficit
At quarter end the company held USD 48.4 million in cash and short-term investments, down from USD 58.5 million at December 31, 2025, and reported a working capital deficit of USD 38.0 million. On November 9, 2026 it closed an underwritten offering of 69,461,520 shares at USD 1.05 each, plus pre-funded warrants, for net proceeds of about USD 80.5 million. Management said that money, with existing cash and later warrant exercises, should fund operations into late fourth quarter 2027 without counting product revenue. Nine-month operating cash use was USD 54.9 million against USD 69.3 million.
VOCERYQ Approval Sets Up a 2027 Launch and a Confirmatory Study
The FDA approved VOCERYQ under its accelerated approval program to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. The trial enrolled 32 adults, and 26 who had three or more surgeries in the prior year formed the efficacy group, where 7 (27%) needed no surgery over 12 months. Common adverse reactions included injection site reactions, headache and fatigue. The company expects a price of about USD 115,000 per dose, or USD 460,000 for the four-dose series, full field deployment in the first quarter of 2027 and a European conditional Marketing application before the end of 2026. Continued approval may depend on a confirmatory study of at least 50 patients, with a draft protocol due by the end of 2026.
Where Things Stand
Inovio Pharmaceuticals (NASDAQ:INO) lost USD 49.2 million mostly because warrant values were marked up, not because operations worsened; the operating loss actually narrowed to USD 19.5 million. The approval of VOCERYQ and the USD 80.5 million raise change the story from a cash squeeze to a launch. Risks remain, including accelerated approval conditions, dilution from the share count rising to 98.6 million weighted shares, and an uncertain pace of orders. Next markers are shipping around 60 days after approval, the confirmatory protocol and the European filing.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...